{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:26Z","timestamp":1783486166764,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the efficacy and safety between denosumab and zoledronic acid for advanced cancer with bone metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, EMBASE, and the Cochrane library databases were searched for randomized controlled trials up to December 2020 that compared denosumab and zoledronic acid in the treatment of advanced cancer with bone metastasis. The following clinical outcomes were extracted for analysis: time to first skeletal-related event, time to first-and-subsequent skeletal-related events, overall survival, and disease progression. Safety outcomes including incidence of adverse events, serious adverse events, acute-phase reactions, renal toxicity, osteonecrosis of the jaw, and hypocalcemia were also extracted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four randomized controlled trials involving 7201 patients were included. The overall analysis showed that denosumab was superior to zoledronic acid in delaying time to first skeletal-related event (hazard ratio = 0.86; 95% confidence interval, 0.80\u20130.93; P &lt; 0.01) and time to first-and-subsequent skeletal-related events (risk ratio 0.87; 95% confidence interval 0.81\u20130.93; P &lt; 0.01). Denosumab was associated with lower incidence of renal toxicity (risk ratio 0.69; 95% confidence interval 0.54\u20130.87; P &lt; 0.01) and acute phase reaction (risk ratio 0.47; 95% confidence interval 0.38\u20130.56; P &lt; 0.01), but higher incidence of hypocalcemia (risk ratio 1.78; 95% confidence interval 1.33\u20132.38; P &lt; 0.01) and osteonecrosis of the jaw (risk ratio 1.41; 95% confidence interval 1.01\u20131.95; P = 0.04). No significant differences were found in overall survival, time to disease progression, or incidence of adverse events and serious adverse events between denosumab and zoledronic acid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with zoledronic acid, denosumab is associated with delayed first-and-subsequent skeletal-related events, lower incidence of renal toxicity, and acute phase reaction, but higher incidence of hypocalcemia and osteonecrosis of the jaw. Hence, denosumab seems to be a promising choice for advanced cancer with bone metastasis. Nonetheless, more randomized controlled trials are needed for further evaluation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-021-02554-8","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T13:12:39Z","timestamp":1624626759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials"],"prefix":"10.1186","volume":"16","author":[{"given":"Lianghai","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-1014","authenticated-orcid":false,"given":"Xiangsheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"20 Pt 2","key":"2554_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s\u20139s.","journal-title":"Clin Cancer Res"},{"issue":"8 Suppl","key":"2554_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588\u201394.","journal-title":"Cancer"},{"issue":"3","key":"2554_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","volume":"168","author":"MG Oefelein","year":"2002","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005\u20137. https:\/\/doi.org\/10.1016\/S0022-5347(05)64561-2.","journal-title":"J Urol"},{"issue":"11","key":"2554_CR4","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.22678","volume":"109","author":"KL Schulman","year":"2007","unstructured":"Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334\u201342.","journal-title":"Cancer"},{"key":"2554_CR5","doi-asserted-by":"publisher","first-page":"104546","DOI":"10.1155\/2013\/104546","volume":"2013","author":"P Tosi","year":"2013","unstructured":"Tosi P. Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica. 2013;2013:104546.","journal-title":"Scientifica."},{"issue":"2","key":"2554_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164\u201375. https:\/\/doi.org\/10.1097\/01.mlr.0000108746.69256.45.","journal-title":"Med Care"},{"issue":"2","key":"2554_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.bjc.6600715","volume":"88","author":"M Noguchi","year":"2003","unstructured":"Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88(2):195\u2013201.","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"2554_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1081\/CNV-120014886","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Investig. 2002;20(Suppl 2):45\u201354. https:\/\/doi.org\/10.1081\/CNV-120014886.","journal-title":"Cancer Investig"},{"issue":"1","key":"2554_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D","volume":"88","author":"PP Major","year":"2000","unstructured":"Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer. 2000;88(1):6\u201314.","journal-title":"Cancer"},{"issue":"12","key":"2554_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","volume":"18","author":"C Gr\u00e1valos","year":"2016","unstructured":"Gr\u00e1valos C, Rodr\u00edguez C, Sabino A, Segu\u00ed M, Virizuela JA, Carmona A, et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol. 2016;18(12):1243\u201353. https:\/\/doi.org\/10.1007\/s12094-016-1590-1.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"2554_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254\u201366. https:\/\/doi.org\/10.3324\/haematol.2014.117176.","journal-title":"Haematologica."},{"issue":"Suppl 3","key":"2554_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2005.09.004","volume":"31","author":"MR Smith","year":"2005","unstructured":"Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005;31(Suppl 3):19\u201325. https:\/\/doi.org\/10.1016\/j.ctrv.2005.09.004.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"2554_CR13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676\u20139 discussion 1676-1679.","journal-title":"N Engl J Med"},{"issue":"1","key":"2554_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281\u20139. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00071.x.","journal-title":"Kidney Int"},{"issue":"6","key":"2554_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.22504","volume":"109","author":"WK Oh","year":"2007","unstructured":"Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007;109(6):1090\u20136.","journal-title":"Cancer"},{"issue":"1","key":"2554_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","volume":"48","author":"A Lipton","year":"2011","unstructured":"Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48(1):96\u20139. https:\/\/doi.org\/10.1016\/j.bone.2010.10.161.","journal-title":"Bone."},{"issue":"2","key":"2554_CR17","first-page":"110","volume":"9","author":"JE Brown","year":"2012","unstructured":"Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature reviews. Clin Oncol. 2012;9(2):110\u20138.","journal-title":"Clin Oncol"},{"issue":"3","key":"2554_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/era.11.204","volume":"12","author":"JJ Body","year":"2012","unstructured":"Body JJ. Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther. 2012;12(3):307\u201322. https:\/\/doi.org\/10.1586\/era.11.204.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2554_CR19","doi-asserted-by":"publisher","unstructured":"Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, et al. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care. 2017;26(6). https:\/\/doi.org\/10.1111\/ecc.12541.","DOI":"10.1111\/ecc.12541"},{"issue":"3","key":"2554_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30072-X.","journal-title":"Lancet Oncol"},{"issue":"9768","key":"2554_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322.","journal-title":"Lancet"},{"issue":"35","key":"2554_CR22","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2554_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679\u201387. https:\/\/doi.org\/10.1007\/s00520-013-2022-1.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2554_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bone.2010.05.038","volume":"48","author":"RJ Lee","year":"2011","unstructured":"Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48(1):88\u201395. https:\/\/doi.org\/10.1016\/j.bone.2010.05.038.","journal-title":"Bone."},{"issue":"11","key":"2554_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879\u201382.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2554_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745\u201355.","journal-title":"N Engl J Med"},{"issue":"28","key":"2554_CR27","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431\u20137.","journal-title":"J Clin Oncol"},{"issue":"30","key":"2554_CR28","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875\u201382.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2554_CR29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2554_CR30","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","volume":"54","author":"C Walter","year":"2008","unstructured":"Walter C, Al-Nawas B, Gr\u00f6tz KA, Thomas C, Th\u00fcroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008;54(5):1066\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2008.06.070.","journal-title":"Eur Urol"},{"issue":"7-8","key":"2554_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000447372","volume":"39","author":"F Chen","year":"2016","unstructured":"Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat. 2016;39(7-8):453\u20139. https:\/\/doi.org\/10.1159\/000447372.","journal-title":"Oncol Res Treat"},{"issue":"16","key":"2554_CR32","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2554_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-021-02554-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:33:39Z","timestamp":1625124819000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-021-02554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1186\/s13018-021-02554-8","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}